Back HIV/AIDS

HIV / AIDS

CROI 2014: Very Different Levels of PrEP Uptake and Adherence in 3 U.S. Cities

One of the first studies of open-label pre-exposure prophylaxis (PrEP) for at-risk gay men in 3 U.S. cities shows that although the proportion of those initially offered or seeking PrEP who ended up taking it was similar in all cities, the amount of interest differed substantially. The demonstration project also found substantial differences in adherence between the cities, possibly due to a younger population in one, but lower adherence was not associated with lower motivation to take PrEP.

alt

CROI 2014: Newborns Exposed to Tenofovir Have Lower Bone Content [VIDEO]

Infants born to women who took tenofovir during pregnancy had significantly lower bone mineral content than babies who were not exposed, according to study findings reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

CROI 2014: Lopinavir or Lamivudine Equally Protective Against HIV During Breast-feeding

Peri-exposure prophylaxis using either lopinavir/ritonavir (Kaletra) or lamivudine (3TC, Epivir) proved equally protective as infant prophylaxis against HIV infection during 12 months of breast-feeding, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

CROI 2014: Dapivirine Vaginal Ring Appears Safe and Effective in Tissue Study

Vaginal rings containing the experimental NNRTI dapivirine were well-tolerated and blocked HIV infection of cervical tissue samples, but rings containing maraviroc did not produce adequate drug concentrations, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

CROI 2014: People with HIV More Likely to Die of Many Common Cancers

People with HIV are more likely to die from many common cancers than the rest of the U.S. population, according to a large comparative study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

CROI 2014: Efavirenz Matches Lopinavir/ritonavir for Perinatal HIV Treatment

Pregnant women taking efavirenz-based antiretroviral therapy (ART) had significantly better virological outcomes at the time of delivery compared to those taking lopinavir/ ritonavir in a randomized study in rural Uganda, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston this month.

alt

CROI 2014: Nipping HIV in the Bud -- Could We Use Genotyping to Interrupt Transmission?

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston heard a number of presentations on phylogenetic analysis -- the use of genetic fingerprinting of HIV to trace patterns of transmission and prioritize groups for targeting prevention.

alt